Literature DB >> 6312824

Ketoconazole protects against infection with Trypanosoma cruzi in a murine model.

R E McCabe, F G Araujo, J S Remington.   

Abstract

The oral administration of ketoconazole to mice protected them against death caused by infection with Trypanosoma cruzi. The addition of ketoconazole to cultures of macrophages infected with the organism markedly inhibited the intracellular multiplication of amastigotes. These observations suggest that ketoconazole may be a potent agent against T. cruzi and should be evaluated more extensively as a chemotherapeutic agent for Chagas' disease.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6312824     DOI： 10.4269/ajtmh.1983.32.960

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN： 0002-9637            Impact factor:   2.345


  10 in total

1.  Comparative efficacy of ketoconazole and mebendazole in experimental trichinosis.

Authors:  J A Hess; P H Chandrasekar; M Mortiere; J A Molinari
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

2.  In vitro activity of ketoconazole against herpes simplex virus.

Authors:  J C Pottage; H A Kessler; J M Goodrich; R Chase; C A Benson; K Kapell; S Levin
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

3.  Mechanisms of invasion and replication of the intracellular stage in Trypanosoma cruzi.

Authors:  R E McCabe; J S Remington; F G Araujo
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

4.  In vitro and in vivo activities of formycin B against Trypanosoma cruzi.

Authors:  R E McCabe; J S Remington; F G Araujo
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

Review 5.  CYP51 as drug targets for fungi and protozoan parasites: past, present and future.

Authors:  Galina I Lepesheva; Laura Friggeri; Michael R Waterman
Journal:  Parasitology       Date:  2018-04-12       Impact factor: 3.234

6.  Synthesis and biological evaluation of N-alkyl naphthoimidazoles derived from β-lapachone against Trypanosoma cruzi bloodstream trypomastigotes.

Authors:  Ari Miranda da Silva; Leonardo Araújo-Silva; Ana Cristina S Bombaça; Rubem F S Menna-Barreto; Claudio Eduardo Rodrigues-Santos; Aurélio B Buarque Ferreira; Solange L de Castro
Journal:  Medchemcomm       Date:  2017-02-27       Impact factor: 3.597

Review 7.  Challenges in the chemotherapy of Chagas disease: Looking for possibilities related to the differences and similarities between the parasite and host.

Authors:  Vitor Sueth-Santiago; Debora Decote-Ricardo; Alexandre Morrot; Celio Geraldo Freire-de-Lima; Marco Edilson Freire Lima
Journal:  World J Biol Chem       Date:  2017-02-26

8.  Assessing anti-T. cruzi candidates in vitro for sterile cidality.

Authors:  Monica Cal; Jean-Robert Ioset; Matthia A Fügi; Pascal Mäser; Marcel Kaiser
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2016-08-26       Impact factor: 4.077

9.  Repurposing of terconazole as an anti Trypanosoma cruzi agent.

Authors:  Chantal Reigada; Melisa Sayé; Edward Valera-Vera; Mariana R Miranda; Claudio A Pereira
Journal:  Heliyon       Date:  2019-06-12

Review 10.  The trypanocidal activity of naphthoquinones: a review.

Authors:  Antônio Ventura Pinto; Solange Lisboa de Castro
Journal:  Molecules       Date:  2009-11-10       Impact factor: 4.927
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.